-
首页
-
- 首页
- WORKSHOP预告
卫生经济学workshop:he Impact of Health Insurance on Survival: Evidence from NCMS in Rural China
发布日期：2016-06-20 09:18 来源：北京大学国家发展研究院
时间：2016年6月20日上午10:30-12:30
地点：万众楼大教室
主持人：刘国恩
主讲人：Karen Eggleston (Stanford University);
Louis P. Garrison (U of Washington)
Topic 1: The Impact of Health Insurance on Survival: Evidence from NCMS in Rural China
Abstract：We aim to provide evidence on whether insurance expansion played a causal role in adult mortality reductions in rural China. We use differences across counties in the timing of the introduction of NCMS to identify its impact on survival. Using data on age-standardized death rates (ADR) per 1000 population from 72 rural counties covered by the Chinese Center for Disease Control and Prevention Disease Surveillance Point (DSP) system from 2004 to 2012, we estimated regressions that included year fixed effects to control for mortality trends that are similar across counties in China; county fixed effects to control for time-invariant, unobservable differences across counties; and county-year-specific variables to control for economic, demographic, and healthcare factors specific to that county and year.
Speaker: Karen Eggleston is Senior Fellow at the Freeman Spogli Institute for International Studies (FSI) at Stanford University, and Director of the Stanford Asia Health Policy Program at the Walter H. Shorenstein Asia-Pacific Research Center at FSI. She is also a Fellow with the Center for Innovation in Global Health at Stanford University School of Medicine, and a Faculty Research Fellow of the National Bureau of Economic Research (NBER). Eggleston earned her PhD in public policy from Harvard University in 1999. She has MA degrees in economics and Asian studies from the University of Hawaii and a BA in Asian studies summa cum laude (valedictorian) from Dartmouth College. Eggleston studied in China for two years and was a Fulbright scholar in Korea. Her research focuses on comparative healthcare systems and health reform in Asia, especially China; government and market roles in the health sector; payment incentives; healthcare productivity; and the economics of the demographic transition. She was a consultant to the World Bank on their project on health service delivery in rural China in 2004, to China's Ministry of Finance and the Asian Development Bank from 2010 to 2011 for an evaluation of China's health reforms, and to the World Bank/WHO/Government of China 2015 study on China's health service delivery system. She is a member of the Strategic Technical Advisory Committee for the Asia Pacific Observatory on Health Systems and Policies.
Topic 2: The Basic Economics of Drug Development and Pricing: Are They Changing?
Abstract：This presentation will review the basic economics of drug development, emphasizing the global public good nature of new medicines. The high and growing fixed costs of development will be described along with the implications of the low marginal cost of production and distribution. The need for global differential pricing to improve access and promote dynamic efficiency will be discussed. While the basic incentives may not be changing, the rising costs of drug development may threaten the sustainability of the industry as we know it. The role of precision medicine and the emerging debate on value frameworks will be discussed.
Speaker: Louis P. Garrison, Jr., PhD, is Professor in the Pharmaceutical Outcomes Research & Policy Program in the School of Pharmacy, and Adjunct Professor in the Departments of Global Health and Health Services at the University of Washington, where he joined the faculty in 2004. He also co-directs the Global Medicines Program in Global Health.For the first 13 years of his career, Dr. Garrison worked in non-profit health policy research first at the Battelle Human Affairs Research Centers (Seattle), and then at the Project HOPE Center for Health Affairs (Virginia), where he was the Director from 1989-1992. Following this, he worked as an economist in the pharmaceutical industry for 12 years. From 2002-2004, he was Vice President and Head of Health Economics & Strategic Pricing in Roche Pharmaceuticals, based in Basel, Switzerland.Dr. Garrison received a BA in Economics from Indiana University, and a PhD in Economics from Stanford University. He has more than 100 publications in peer-reviewed journals. His research interests include national and international health policy issues related to personalized medicine, benefit-risk analysis, insurance, pricing, reimbursement, and risk-sharing agreements, as well as the economic evaluation of pharmaceuticals, diagnostics, devices, surgical procedures, and vaccines, particularly as related to organ transplantation, influenza, measles, obesity, and cancer.From 2007-2009, Dr. Garrison served on the ISPOR Board of Directors. He co-chaired two ISPOR Good Practice Task Forces—on Real-World Data and on Performance-Based Risk-Sharing Arrangements—and he chaired the ISPOR Health Science Policy Council from 2012 to 2015. He is faculty advisor for the UW ISPOR Student Chapter. He was elected as ISPOR President for July 2016-June, 2017, and will serve on the Board for following year as Past President.
国家发展研究院官方微信
Copyright© 1994-2012 北京大学 国家发展研究院 版权所有, 京ICP备05065075号-1
保留所有权利，不经允许请勿挪用
-
首页
-
卫生经济学workshop:he Impact of Health Insurance on Survival: Evidence from NCMS in Rural China
发布日期：2016-06-20 09:18 来源：北京大学国家发展研究院
时间：2016年6月20日上午10:30-12:30
地点：万众楼大教室
主持人：刘国恩
主讲人：Karen Eggleston (Stanford University);
Louis P. Garrison (U of Washington)
Topic 1: The Impact of Health Insurance on Survival: Evidence from NCMS in Rural China
Abstract：We aim to provide evidence on whether insurance expansion played a causal role in adult mortality reductions in rural China. We use differences across counties in the timing of the introduction of NCMS to identify its impact on survival. Using data on age-standardized death rates (ADR) per 1000 population from 72 rural counties covered by the Chinese Center for Disease Control and Prevention Disease Surveillance Point (DSP) system from 2004 to 2012, we estimated regressions that included year fixed effects to control for mortality trends that are similar across counties in China; county fixed effects to control for time-invariant, unobservable differences across counties; and county-year-specific variables to control for economic, demographic, and healthcare factors specific to that county and year.
Speaker: Karen Eggleston is Senior Fellow at the Freeman Spogli Institute for International Studies (FSI) at Stanford University, and Director of the Stanford Asia Health Policy Program at the Walter H. Shorenstein Asia-Pacific Research Center at FSI. She is also a Fellow with the Center for Innovation in Global Health at Stanford University School of Medicine, and a Faculty Research Fellow of the National Bureau of Economic Research (NBER). Eggleston earned her PhD in public policy from Harvard University in 1999. She has MA degrees in economics and Asian studies from the University of Hawaii and a BA in Asian studies summa cum laude (valedictorian) from Dartmouth College. Eggleston studied in China for two years and was a Fulbright scholar in Korea. Her research focuses on comparative healthcare systems and health reform in Asia, especially China; government and market roles in the health sector; payment incentives; healthcare productivity; and the economics of the demographic transition. She was a consultant to the World Bank on their project on health service delivery in rural China in 2004, to China's Ministry of Finance and the Asian Development Bank from 2010 to 2011 for an evaluation of China's health reforms, and to the World Bank/WHO/Government of China 2015 study on China's health service delivery system. She is a member of the Strategic Technical Advisory Committee for the Asia Pacific Observatory on Health Systems and Policies.
Topic 2: The Basic Economics of Drug Development and Pricing: Are They Changing?
Abstract：This presentation will review the basic economics of drug development, emphasizing the global public good nature of new medicines. The high and growing fixed costs of development will be described along with the implications of the low marginal cost of production and distribution. The need for global differential pricing to improve access and promote dynamic efficiency will be discussed. While the basic incentives may not be changing, the rising costs of drug development may threaten the sustainability of the industry as we know it. The role of precision medicine and the emerging debate on value frameworks will be discussed.
Speaker: Louis P. Garrison, Jr., PhD, is Professor in the Pharmaceutical Outcomes Research & Policy Program in the School of Pharmacy, and Adjunct Professor in the Departments of Global Health and Health Services at the University of Washington, where he joined the faculty in 2004. He also co-directs the Global Medicines Program in Global Health.For the first 13 years of his career, Dr. Garrison worked in non-profit health policy research first at the Battelle Human Affairs Research Centers (Seattle), and then at the Project HOPE Center for Health Affairs (Virginia), where he was the Director from 1989-1992. Following this, he worked as an economist in the pharmaceutical industry for 12 years. From 2002-2004, he was Vice President and Head of Health Economics & Strategic Pricing in Roche Pharmaceuticals, based in Basel, Switzerland.Dr. Garrison received a BA in Economics from Indiana University, and a PhD in Economics from Stanford University. He has more than 100 publications in peer-reviewed journals. His research interests include national and international health policy issues related to personalized medicine, benefit-risk analysis, insurance, pricing, reimbursement, and risk-sharing agreements, as well as the economic evaluation of pharmaceuticals, diagnostics, devices, surgical procedures, and vaccines, particularly as related to organ transplantation, influenza, measles, obesity, and cancer.From 2007-2009, Dr. Garrison served on the ISPOR Board of Directors. He co-chaired two ISPOR Good Practice Task Forces—on Real-World Data and on Performance-Based Risk-Sharing Arrangements—and he chaired the ISPOR Health Science Policy Council from 2012 to 2015. He is faculty advisor for the UW ISPOR Student Chapter. He was elected as ISPOR President for July 2016-June, 2017, and will serve on the Board for following year as Past President.
访问学者申请
EMAIL
北京大学
ENGLISH
